flutter. allowed to whereas 7 of receive 57 pts (12%) label diltiazem responded to if placebo had placebo. been given. Van Efficacy 81 pts N/A N/A Chronic AF or flutter Age <16 or >80 y; Multiple N/A N/A N/A 9% of pts Gelder and CHF or angina regression treated w/ IC safety of pectoris > III (NYHA); analysis flecainide had 1989 MI <2 y, flecainide showed New adverse (181) intolerance, BBB, York Heart events acetate SSS w/o pacemaker, Association (e.g,sinus in the antiarrhythmics, class I for arrest, AV severe systemic exercise block, rate of disease tolerance related sinus (p=0.0004) LBBB). rhythm and flecainide Moderate after treatment doses of electrical (p=0.01) to be flecainide (not the main >300 mg) of factors recommended chronic increasing the after AF or cardioversion atrial episode. flutter. However, Mantel-Cox lifetable analysis did not reveal significant differences between survival curves of both treatment groups. In the group, 9% of pts experienced side effects, mostly related to negative dromotropic effects. The incidence of ventricular proarrhythmia
flutter. allowed to receive diltiazem if placebo had been given. whereas 7 of 57 pts (12%) responded to placebo. Van Gelder IC 1989 (181) Efficacy and safety of acetate in the of sinus rhythm after electrical of chronic AF or atrial flutter. 81 pts N/A N/A Chronic AF or flutter Age <16 or >80 y; CHF or angina pectoris > III (NYHA); MI <2 y, flecainide intolerance, BBB, SSS w/o pacemaker, antiarrhythmics, severe systemic disease Multiple regression analysis showed New York Heart Association class I for exercise tolerance (p=0.0004) and flecainide treatment (p=0.01) to be the main factors increasing the episode. However, Mantel-Cox lifetable analysis did not reveal significant differences between survival curves of both treatment groups. In the group, 9% of pts experienced side effects, mostly related to negative dromotropic effects. The incidence of ventricular proarrhythmia N/A N/A N/A 9% of pts treated w/ flecainide had adverse events (e.g,sinus arrest, AV block, rate related LBBB). Moderate doses of flecainide (not >300 mg) recommended after cardioversion label
2015_SVT_Evidence_Tables_Data_Supplement.docx